Bill Text: IA SF404 | 2017-2018 | 87th General Assembly | Introduced
NOTE: There are more recent revisions of this legislation. Read Latest Draft
Bill Title: A bill for an act relating to the use of experimental treatments for patients with a terminal illness. (Formerly SSB 1115.) Effective 7-1-17.
Spectrum: Committee Bill
Status: (Passed) 2017-05-11 - Signed by Governor. S.J. 1135. [SF404 Detail]
Download: Iowa-2017-SF404-Introduced.html
Bill Title: A bill for an act relating to the use of experimental treatments for patients with a terminal illness. (Formerly SSB 1115.) Effective 7-1-17.
Spectrum: Committee Bill
Status: (Passed) 2017-05-11 - Signed by Governor. S.J. 1135. [SF404 Detail]
Download: Iowa-2017-SF404-Introduced.html
Senate File 404 - Introduced SENATE FILE BY COMMITTEE ON COMMERCE (SUCCESSOR TO SSB 1115) A BILL FOR 1 An Act relating to the use of experimental treatments for 2 patients with a terminal illness. 3 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA: TLSB 1882SV (1) 87 tr/nh PAG LIN 1 1 Section 1. NEW SECTION. 144E.1 Title. 1 2 This chapter shall be known and may be cited as the "Right 1 3 to Try Act". 1 4 Sec. 2. NEW SECTION. 144E.2 Definitions. 1 5 As used in this chapter: 1 6 1. "Eligible patient" means an individual who meets all of 1 7 the following conditions: 1 8 a. Has a terminal illness, attested to by the patient's 1 9 treating physician. 1 10 b. Has considered and rejected or has tried and failed to 1 11 respond to all other treatment options approved by the United 1 12 States food and drug administration. 1 13 c. Has received a recommendation from the individual's 1 14 physician for an investigational drug, biological product, or 1 15 device. 1 16 d. Has given written informed consent for the use of the 1 17 investigational drug, biological product, or device. 1 18 e. Has documentation from the individual's physician that 1 19 the individual meets the requirements of this subsection. 1 20 2. "Investigational drug, biological product, or device" 1 21 means a drug, biological product, or device that has 1 22 successfully completed phase 1 of a United States food and drug 1 23 administration=approved clinical trial but has not yet been 1 24 approved for general use by the United States food and drug 1 25 administration and remains under investigation in a United 1 26 States food and drug administration=approved clinical trial. 1 27 3. "Terminal illness" means a progressive disease or medical 1 28 or surgical condition that entails significant functional 1 29 impairment, that is not considered by a treating physician to 1 30 be reversible even with administration of treatments approved 1 31 by the United States food and drug administration, and that, 1 32 without life=sustaining procedures, will result in death. 1 33 4. "Written informed consent" means a written document that 1 34 is signed by the patient, a parent of a minor patient, or a 1 35 legal guardian or other legal representative of the patient and 2 1 attested to by the patient's treating physician and a witness 2 2 and that includes all of the following: 2 3 a. An explanation of the products and treatments approved by 2 4 the United States food and drug administration for the disease 2 5 or condition from which the patient suffers. 2 6 b. An attestation that the patient concurs with the 2 7 patient's treating physician in believing that all products 2 8 and treatments approved by the United States food and drug 2 9 administration are unlikely to prolong the patient's life. 2 10 c. Clear identification of the specific proposed 2 11 investigational drug, biological product, or device that the 2 12 patient is seeking to use. 2 13 d. A description of the best and worst potential outcomes 2 14 of using the investigational drug, biological product, or 2 15 device and a realistic description of the most likely outcome. 2 16 The description shall include the possibility that new, 2 17 unanticipated, different, or worse symptoms might result 2 18 and that death could be hastened by use of the proposed 2 19 investigational drug, biological product, or device. The 2 20 description shall be based on the treating physician's 2 21 knowledge of the proposed investigational drug, biological 2 22 product, or device in conjunction with an awareness of the 2 23 patient's condition. 2 24 e. A statement that the patient's health plan or third=party 2 25 administrator and provider are not obligated to pay for any 2 26 care or treatments consequent to the use of the investigational 2 27 drug, biological product, or device, unless they are 2 28 specifically required to do so by law or contract. 2 29 f. A statement that the patient's eligibility for hospice 2 30 care may be withdrawn if the patient begins curative treatment 2 31 with the investigational drug, biological product, or device 2 32 and that care may be reinstated if this treatment ends and the 2 33 patient meets hospice eligibility requirements. 2 34 g. A statement that the patient understands that the 2 35 patient is liable for all expenses consequent to the use of 3 1 the investigational drug, biological product, or device and 3 2 that this liability extends to the patient's estate unless 3 3 a contract between the patient and the manufacturer of the 3 4 investigational drug, biological product, or device states 3 5 otherwise. 3 6 Sec. 3. NEW SECTION. 144E.3 Manufacturer rights. 3 7 1. A manufacturer of an investigational drug, biological 3 8 product, or device may make available and an eligible patient 3 9 may request the manufacturer's investigational drug, biological 3 10 product, or device under this chapter. This chapter does not 3 11 require a manufacturer of an investigational drug, biological 3 12 product, or device to provide or otherwise make available the 3 13 investigational drug, biological product, or device to an 3 14 eligible patient. 3 15 2. A manufacturer described in subsection 1 may do any of 3 16 the following: 3 17 a. Provide an investigational drug, biological product, or 3 18 device to an eligible patient without receiving compensation. 3 19 b. Require an eligible patient to pay the costs of, or the 3 20 costs associated with, the manufacture of the investigational 3 21 drug, biological product, or device. 3 22 Sec. 4. NEW SECTION. 144E.4 Treatment coverage. 3 23 1. This chapter does not expand the coverage required of an 3 24 insurer under Title XIII, subtitle 1. 3 25 2. A health plan, third=party administrator, or 3 26 governmental agency may provide coverage for the cost of an 3 27 investigational drug, biological product, or device, or the 3 28 cost of services related to the use of an investigational drug, 3 29 biological product, or device under this chapter. 3 30 3. This chapter does not require any governmental agency 3 31 to pay costs associated with the use, care, or treatment of a 3 32 patient with an investigational drug, biological product, or 3 33 device. 3 34 4. This chapter does not require a hospital licensed under 3 35 chapter 135B or other health care facility to provide new or 4 1 additional services. 4 2 Sec. 5. NEW SECTION. 144E.5 Heirs not liable for treatment 4 3 debts. 4 4 If a patient dies while being treated by an investigational 4 5 drug, biological product, or device, the patient's heirs are 4 6 not liable for any outstanding debt related to the treatment 4 7 or lack of insurance due to the treatment, unless otherwise 4 8 required by law. 4 9 Sec. 6. NEW SECTION. 144E.6 Provider recourse. 4 10 1. To the extent consistent with state law, the board of 4 11 medicine created under chapter 147 shall not revoke, fail 4 12 to renew, suspend, or take any action against a physician's 4 13 license based solely on the physician's recommendations to 4 14 an eligible patient regarding access to or treatment with an 4 15 investigational drug, biological product, or device. 4 16 2. To the extent consistent with federal law, an entity 4 17 responsible for Medicare certification shall not take action 4 18 against a physician's Medicare certification based solely on 4 19 the physician's recommendation that a patient have access to an 4 20 investigational drug, biological product, or device. 4 21 Sec. 7. NEW SECTION. 144E.7 State interference. 4 22 An official, employee, or agent of this state shall not 4 23 block or attempt to block an eligible patient's access to 4 24 an investigational drug, biological product, or device. 4 25 Counseling, advice, or a recommendation consistent with medical 4 26 standards of care from a licensed physician is not a violation 4 27 of this section. 4 28 Sec. 8. NEW SECTION. 144E.8 Private cause of action. 4 29 1. This chapter shall not create a private cause of 4 30 action against a manufacturer of an investigational drug, 4 31 biological product, or device or against any other person 4 32 or entity involved in the care of an eligible patient using 4 33 the investigational drug, biological product, or device 4 34 for any harm done to the eligible patient resulting from 4 35 the investigational drug, biological product, or device, if 5 1 the manufacturer or other person or entity is complying in 5 2 good faith with the terms of this chapter and has exercised 5 3 reasonable care. 5 4 2. This chapter shall not affect any mandatory health care 5 5 coverage for participation in clinical trials under Title XIII, 5 6 subtitle 1. 5 7 EXPLANATION 5 8 The inclusion of this explanation does not constitute agreement with 5 9 the explanation's substance by the members of the general assembly. 5 10 This bill, titled the "Right to Try Act", permits 5 11 manufacturers of investigational drugs, biological products, or 5 12 devices to make available, and eligible patients with terminal 5 13 illnesses to attempt treatment with, an investigational 5 14 drug, biological product, or device as long as they provided 5 15 written informed consent. The bill defines the terms "eligible 5 16 patient", "terminal illness", "investigational drug, biological 5 17 product, or device", and "written informed consent". 5 18 Under the bill, an eligible patient's physician must 5 19 acknowledge that the patient's illness is terminal and 5 20 recommend the patient try an investigational drug, biological 5 21 product, or device. The patient's written informed consent 5 22 must acknowledge that treatments currently approved by the 5 23 United Stated food and drug administration are unlikely to 5 24 prolong the patient's life. It must identify the specific 5 25 treatment sought and the potential best, worst, and expected 5 26 results from the treatment. It must acknowledge that the 5 27 patient's insurance is not required to pay for the treatment 5 28 and that any hospice service may refuse to accept the patient 5 29 after receiving the treatment. It must also acknowledge 5 30 that expenses will be credited to the patient, including the 5 31 patient's estate, unless an agreement with the manufacturer of 5 32 an investigational drug, biological product, or device states 5 33 otherwise. If the patient dies during treatment, the patient's 5 34 heirs are not liable for any remaining debts unless otherwise 5 35 required by law. 6 1 The manufacturer of an investigational drug, biological 6 2 product, or device may charge an eligible patient or provide 6 3 the treatment free of charge. Governmental entities are 6 4 not required to pay costs associated with the use, care, 6 5 or treatment of a patient with an investigational drug, 6 6 biological product, or device. The bill does not require 6 7 hospitals licensed under Code chapter 135B or other health care 6 8 facilities to provide new or additional services. 6 9 Consistent with existing law, the board of medicine shall 6 10 not take an adverse action against a physician's license solely 6 11 for recommending an investigational drug, biological product, 6 12 or device for the physician's eligible patient. The bill does 6 13 not create a new private cause of action against any person or 6 14 entity involved in the care of an eligible patient using the 6 15 investigational drug, biological product, or device for any 6 16 harm done to the patient resulting from the treatment if the 6 17 person or entity is complying in good faith with the terms of 6 18 the bill and has exercised reasonable care. LSB 1882SV (1) 87 tr/nh